These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1305 related articles for article (PubMed ID: 26209472)

  • 1. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
    Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
    Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
    Goedert M
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases.
    Hart de Ruyter FJ; Evers MJAP; Morrema THJ; Dijkstra AA; den Haan J; Twisk JWR; de Boer JF; Scheltens P; Bouwman FH; Verbraak FD; Rozemuller AJ; Hoozemans JJM
    Acta Neuropathol; 2024 Aug; 148(1):24. PubMed ID: 39160362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
    Krüger R; Müller T; Riess O
    J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases.
    Giacomelli C; Daniele S; Martini C
    Biochem Pharmacol; 2017 May; 131():1-15. PubMed ID: 28159621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.
    Duka V; Lee JH; Credle J; Wills J; Oaks A; Smolinsky C; Shah K; Mash DC; Masliah E; Sidhu A
    PLoS One; 2013; 8(9):e75025. PubMed ID: 24073234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?
    Yan X; Uronen RL; Huttunen HJ
    Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 and neurodegeneration.
    Santpere G; Ferrer I
    Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
    Sengupta U; Kayed R
    Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycation in Parkinson's disease and Alzheimer's disease.
    Vicente Miranda H; El-Agnaf OM; Outeiro TF
    Mov Disord; 2016 Jun; 31(6):782-90. PubMed ID: 26946341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplicity of α-Synuclein Aggregated Species and Their Possible Roles in Disease.
    Gracia P; Camino JD; Volpicelli-Daley L; Cremades N
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
    Coskuner-Weber O; Uversky VN
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
    Dominguez-Meijide A; Vasili E; König A; Cima-Omori MS; Ibáñez de Opakua A; Leonov A; Ryazanov S; Zweckstetter M; Griesinger C; Outeiro TF
    Sci Rep; 2020 Jul; 10(1):12827. PubMed ID: 32732936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.
    Trojanowski JQ; Goedert M; Iwatsubo T; Lee VM
    Cell Death Differ; 1998 Oct; 5(10):832-7. PubMed ID: 10203692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein and tau: teammates in neurodegeneration?
    Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
    Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein.
    Goedert M
    Science; 2015 Aug; 349(6248):1255555. PubMed ID: 26250687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
    Hauw JJ; Hausser-Hauw C; Duyckaerts C
    Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
    Dev KK; Hofele K; Barbieri S; Buchman VL; van der Putten H
    Neuropharmacology; 2003 Jul; 45(1):14-44. PubMed ID: 12814657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview.
    Matej R; Tesar A; Rusina R
    Clin Biochem; 2019 Nov; 73():26-31. PubMed ID: 31400306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.